Blueprint Medicines (BPMC) Misses Q4 EPS by 12c, Miss on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% as AI buildout costs, Fed rate outlook weigh
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Blueprint Medicines (BPMC) PT Raised to $98 at Wedbush
February 22, 2018 3:28 PM ESTWedbush raised its price target on Blueprint Medicines (NASDAQ: BPMC) to $98.00 (from $96.00) while maintaining a Outperform rating.
Analyst David Nierengarten commented, "In addition to working toward enrollment of the registration-directed PDGFR-driven GIST trial set to complete mid-year, BPMC has moved... More
